Start LEQEMBI. Change the course of AD1,2
In an 18-month study, LEQEMBI was proven to slow the progression of MCI due to AD and mild AD dementia. Learn more:
The Centers for Medicare & Medicaid Services (CMS) has released information regarding coverage of new Alzheimer’s drugs for Medicare patients. For more information, click here.
CMS has updated the list of approved studies for Coverage with Evidence Development (CED) of amyloid PET scans to include the two studies currently approved under the National Coverage Determination (NCD) for anti-amyloid-β monoclonal antibodies. For more information, refer to this link or contact your local Medicare Administrative Contractor.
To learn about Eisai Patient Support for patients prescribed LEQEMBI, call 1-833-4-LEQEMBI (1-833-453-7362) or click here.
